|Bid||225.56 x 1200|
|Ask||225.80 x 800|
|Day's range||224.75 - 227.44|
|52-week range||197.47 - 306.08|
|Beta (5Y monthly)||0.78|
|PE ratio (TTM)||22.11|
|Earnings date||28 Jan 2021 - 01 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||285.58|
The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals
Last year, companies working on coronavirus vaccines led gains in biotech stocks. Considering these elements, here are my top biotech stocks to buy in 2021. Moderna (NASDAQ: MRNA) shares climbed more than 430% last year.
If you want sizzling returns, look no further than the biotech industry. The SPDR S&P Biotech ETF (NYSEMKT: XBI) -- a pretty good barometer for biotechs -- delivered a 48% gain last year. That marked the best performance for the ETF since 2013, when it soared by roughly the same amount.